Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Viral Hepat. 2018 May;25(5):608-611. doi: 10.1111/jvh.12840. Epub 2017 Dec 28.

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.

Author information

1
Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
2
Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
3
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
4
Department of Hepatology, Osaka City General Hospital, Osaka, Japan.
5
The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
6
Department of Gastroenterology and Neurology Faculty of Medicine, Kagawa University, Kagawa, Japan.
7
Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.

Abstract

To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free antihepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients and paritaprevir plus ombitasvir and ritonavir to 25 patients. In total, 167 patients with genotype 2 were treated with SOF plus ribavirin. Three patients with an HBV DNA level ≥2000 IU/mL were treated with entecavir before anti-HCV therapy, without reactivation of HBV. In 3 of 22 (12%) HBV surface antigen (HBsAg)-positive patients with an HBV DNA level <2000 IU/mL, the viral load increased during treatment. However, hepatitis flare did not occur in these patients. There was no significant difference in clinical history between patients with and without HBV reactivation. Among 765 patients with resolved HBV infection, HBV reactivation occurred in 1 (0.1%) patient after initial resolution, whose HBV DNA level spontaneously decreased after DAA therapy. We compared anti-HBs titres at baseline with those at post-DAA therapy in 123 patients without HBsAg. There was no significant difference in anti-HBs levels between the two points (P = .79). In conclusion, HBV reactivation was rare in HBsAg-negative patients treated with DAA therapy. Additionally, hepatitis did not occur in HBV-reactivated patients with a baseline HBV DNA level <2000 IU/mL before DAA therapy.

KEYWORDS:

antihepatitis B surface antigen; direct-acting antiviral agents; hepatitis B virus; hepatitis C virus; reactivation

PMID:
29194858
DOI:
10.1111/jvh.12840
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center